BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:UB-VV500 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of UB-VV500\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07735546-3328@assetmemo.bio
DTSTAMP:20261121T005700Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:UB-VV500: Phase 1 readout est. (NCT07735546)
DESCRIPTION:UB-VV500\, phase 1\, Multiple Myeloma.\nStudy: A Phase 1 Study 
 of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma\nEstima
 ted primary completion: 31 December 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ub-vv500#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07735546
URL:https://assetmemo.bio/drug/ub-vv500#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
